poor man's semaglutide You've reached your weight loss goal on GLP-1 medications – what now? The "poor man's Ozempic".

Promotes fullness by slowing digestion, helping patients feel satisfied with smaller meals

in clinical studies, an increase in hypoglycemia incidence was only observed in tirzepatide-treated patients if they had a comedication with insulin and/or oral insulinotropic agents (sulfonylurea) (61)

Key considerations include: The safety profile of weight loss injections in patients with dyslipidaemia Potential interactions with lipid-lowering medications The impact of weight loss itself on cholesterol levels Individual cardiovascular risk assessment Clinical evidence suggests that GLP-1 receptor agonists may have beneficial effects on lipid profiles beyond their primary weight loss action

This approach isolates the effect of increasing or decreasing training load relative to one's usual routine , rather than absolute exercise volume

If you do not have metabolic disease, the idea of using GLP-1 purely for dementia prevention is more speculative